JPET Assistant Professor of Medicine (Clinician-Educator)

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hakkola, J.
Right arrow Articles by Ingelman-Sundberg, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hakkola, J.
Right arrow Articles by Ingelman-Sundberg, M.

Vol. 304, Issue 3, 1048-1054, March 2003

Mechanisms of Down-Regulation of CYP2E1 Expression by Inflammatory Cytokines in Rat Hepatoma Cells

Jukka Hakkola, Yin Hu and Magnus Ingelman-Sundberg

Department of Pharmacology and Toxicology, University of Oulu, Oulu, Finland (J.H.); Astrazeneca R&D Södertälje, Research DMPK, Södertälje, Sweden (Y.H.); and Division of Molecular Toxicology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden (M.I.-S.)

CYP2E1 is one of the major cytochrome P450 forms whose expression is strongly inhibited by inflammatory cytokines in humans and rodents. In the present study, we have used the Fao rat hepatoma cell line that constitutively expresses CYP2E1 enzyme to investigate mechanisms of cytokine action. The cells were treated with interleukin (IL)-1beta , tumor necrosis factor-alpha (TNFalpha ), or IL-6 for 24 or 72 h, and the expression of CYP2E1 was monitored at the transcriptional, mRNA, and protein levels. All three cytokines decreased the CYP2E1 mRNA levels after 24 h, and the effect was even stronger after 72 h. In contrast, significant inhibition of CYP2E1 protein was seen only after 72 h. In transfection assays using a CYP2E1 5' -3685 to +29-luciferase construct, it was found that IL-6 inhibited gene transcription after 24 h, but a similar effect by IL-1beta and TNFalpha was registered only after 72 h. Using 5' deletions of the CYP2E1 5'-reporter construct a responsive region for the IL-6 effect was located to -669 to -507 base pairs in the CYP2E1 5'-flanking region. Interestingly, IL-1beta , but not TNFalpha , was found to reduce hepatocyte nuclear factor (HNF)-1alpha binding to the CYP2E1 promotor. However, the transactivation function of HNF-1alpha was found to be impaired in Fao cells. In mouse primary hepatocytes, IL-1beta decreased HNF-1alpha -mediated transactivation. In conclusion, our data indicate that inflammatory cytokines inhibit CYP2E1 expression by multiple mechanisms, including control of HNF-1alpha function and regulation of other transcriptional factors acting on the CYP2E1 5'-upstream regulatory region. In addition, regulation of factors of importance for the CYP2E1 mRNA stability may be involved.


0022-3565/03/3043-1048$07.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 2003 by The American Society for Pharmacology and Experimental Therapeutics



This article has been cited by other articles:


Home page
Drug Metab. Dispos.Home page
K. Nakai, H. Tanaka, K. Hanada, H. Ogata, F. Suzuki, H. Kumada, A. Miyajima, S. Ishida, M. Sunouchi, W. Habano, et al.
Decreased Expression of Cytochromes P450 1A2, 2E1, and 3A4 and Drug Transporters Na+-Taurocholate-Cotransporting Polypeptide, Organic Cation Transporter 1, and Organic Anion-Transporting Peptide-C Correlates with the Progression of Liver Fibrosis in Chronic Hepatitis C Patients
Drug Metab. Dispos., September 1, 2008; 36(9): 1786 - 1793.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
S. Arpiainen, F. Raffalli-Mathieu, M. A. Lang, O. Pelkonen, and J. Hakkola
Regulation of the Cyp2a5 Gene Involves an Aryl Hydrocarbon Receptor-Dependent Pathway
Mol. Pharmacol., April 1, 2005; 67(4): 1325 - 1333.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
I-N. Park, I. J. Cho, and S. G. Kim
Ceramide Negatively Regulates Glutathione S-transferase Gene Transactivation via Repression of Hepatic Nuclear Factor-1 That Is Degraded by the Ubiquitin Proteasome System
Mol. Pharmacol., June 1, 2004; 65(6): 1475 - 1484.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
P. Kelicen and N. Tindberg
Lipopolysaccharide Induces CYP2E1 in Astrocytes through MAP Kinase Kinase-3 and C/EBP{beta} and -{delta}
J. Biol. Chem., April 16, 2004; 279(16): 15734 - 15742.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
L. O. Qiu, M. W. Linder, D. M. Antonino-Green, and R. Valdes Jr.
Suppression of Cytochrome P450 2E1 Promoter Activity by Interferon-{gamma} and Loss of Response Due to the -71G>T Nucleotide Polymorphism of the CYP2E1*7B Allele
J. Pharmacol. Exp. Ther., January 1, 2004; 308(1): 284 - 288.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2003 by the American Society for Pharmacology and Experimental Therapeutics.